11.27
price up icon1.08%   0.12
pre-market  Pre-market:  11.04   -0.23   -2.04%
loading
Roivant Sciences Ltd stock is traded at $11.27, with a volume of 4.25M. It is up +1.08% in the last 24 hours and down -2.59% over the past month. Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
See More
Previous Close:
$11.15
Open:
$11.22
24h Volume:
4.25M
Relative Volume:
0.94
Market Cap:
$8.20B
Revenue:
$125.68M
Net Income/Loss:
$4.81B
P/E Ratio:
1.9947
EPS:
5.65
Net Cash Flow:
$-781.21M
1W Performance:
+3.02%
1M Performance:
-2.59%
6M Performance:
+2.45%
1Y Performance:
+8.89%
1-Day Range:
Value
$11.12
$11.38
1-Week Range:
Value
$10.89
$11.38
52-Week Range:
Value
$9.69
$13.05

Roivant Sciences Ltd Stock (ROIV) Company Profile

Name
Name
Roivant Sciences Ltd
Name
Phone
441-295-5950
Name
Address
CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON HM11
Name
Employee
908
Name
Twitter
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
ROIV's Discussions on Twitter

Compare ROIV with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ROIV
Roivant Sciences Ltd
11.27 8.20B 125.68M 4.81B -781.21M 5.65
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
427.89 110.19B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
687.80 75.58B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
647.39 38.71B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
264.99 34.18B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.25 28.11B 3.30B -501.07M 1.03B -2.1146

Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-15-24 Initiated Wolfe Research Outperform
Jan-05-24 Initiated Piper Sandler Overweight
Dec-12-23 Initiated Deutsche Bank Buy
Oct-17-23 Initiated Guggenheim Buy
Jun-08-23 Initiated BofA Securities Neutral
Oct-27-22 Initiated JP Morgan Overweight
May-23-22 Initiated SVB Leerink Outperform
Apr-29-22 Initiated Cantor Fitzgerald Overweight
Dec-15-21 Initiated Goldman Buy
Nov-08-21 Initiated H.C. Wainwright Buy
Oct-28-21 Initiated Citigroup Buy
Oct-26-21 Initiated Cowen Outperform
Oct-26-21 Initiated Jefferies Buy
Oct-26-21 Initiated Truist Buy
View All

Roivant Sciences Ltd Stock (ROIV) Latest News

pulisher
Jan 20, 2025

What Is Vivek Ramaswamy’s net worth? The Indian American man who took on Trump and then became a confidante - The Financial Express

Jan 20, 2025
pulisher
Jan 18, 2025

Trump Inauguration: Who Is Vivek Ramaswamy and what’s his role in Trump 2.0? - The Financial Express

Jan 18, 2025
pulisher
Jan 18, 2025

Roivant Sciences Sees Unusually High Options Volume (NASDAQ:ROIV) - MarketBeat

Jan 18, 2025
pulisher
Jan 17, 2025

Roivant Sciences Ltd. Trade Ideas — LS:A3C4MS - TradingView

Jan 17, 2025
pulisher
Jan 15, 2025

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Acquires $336,900,200.00 in Stock - MarketBeat

Jan 15, 2025
pulisher
Jan 15, 2025

Roivant sciences increases stake in Immunovant with $336.9 million purchase By Investing.com - Investing.com Nigeria

Jan 15, 2025
pulisher
Jan 15, 2025

Roivant sciences increases stake in Immunovant with $336.9 million purchase - Investing.com

Jan 15, 2025
pulisher
Jan 12, 2025

Is Roivant Sciences (ROIV) the Best Medical Stock to Buy Under $20? - Insider Monkey

Jan 12, 2025
pulisher
Jan 11, 2025

12 Best Medical Stocks To Buy Under $20 - Insider Monkey

Jan 11, 2025
pulisher
Jan 11, 2025

Nordea Investment Management AB Raises Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat

Jan 11, 2025
pulisher
Jan 10, 2025

ROIVWroivw Latest Stock News & Market Updates - StockTitan

Jan 10, 2025
pulisher
Jan 08, 2025

ROIV Crosses Below Key Moving Average Level - Nasdaq

Jan 08, 2025
pulisher
Jan 07, 2025

Arbutus could benefit from Big Pharma bird flu vaccines: Jefferies - MSN

Jan 07, 2025
pulisher
Jan 06, 2025

Why Ramaswamy Says America Needs a Cultural Shift Towards Excellence for the Sake of US Students - The Times of India

Jan 06, 2025
pulisher
Jan 03, 2025

Roivant Sciences Ltd. (NASDAQ:ROIV) Receives $17.93 Consensus Target Price from Analysts - MarketBeat

Jan 03, 2025
pulisher
Jan 02, 2025

Why Roivant Sciences Ltd. (ROIV) Is Skyrocketing - Yahoo Finance

Jan 02, 2025
pulisher
Jan 01, 2025

10 Firms End 2024 Stronger With Impressive Gains - Insider Monkey

Jan 01, 2025
pulisher
Jan 01, 2025

Strategic Sale: Eric Venker Decides To Exercise Options Worth $3.86M At Roivant Sciences - Benzinga

Jan 01, 2025
pulisher
Dec 31, 2024

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $2,050,704.16 in Stock - MarketBeat

Dec 31, 2024
pulisher
Dec 31, 2024

Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 176,900 Shares of Stock - MarketBeat

Dec 31, 2024
pulisher
Dec 31, 2024

Roivant Sciences' president sells common shares worth $4.1 million - Investing.com India

Dec 31, 2024
pulisher
Dec 30, 2024

Principal Financial Group Inc. Has $11.65 Million Position in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat

Dec 30, 2024
pulisher
Dec 27, 2024

Roivant Sciences' CIO Mayukh Sukhatme sells $10.6m in shares - Investing.com India

Dec 27, 2024
pulisher
Dec 26, 2024

Eric Venker Sells 100,000 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock - MarketBeat

Dec 26, 2024
pulisher
Dec 26, 2024

Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) CIO Sells 689,495 Shares of Stock - MarketBeat

Dec 26, 2024
pulisher
Dec 26, 2024

Mayukh Sukhatme Sells 185,946 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock - MarketBeat

Dec 26, 2024
pulisher
Dec 26, 2024

Roivant sciences president Eric Venker sells $1.15 million in shares By Investing.com - Investing.com Nigeria

Dec 26, 2024
pulisher
Dec 26, 2024

Roivant Sciences’ CIO Mayukh Sukhatme sells $10.6m in shares By Investing.com - Investing.com Nigeria

Dec 26, 2024
pulisher
Dec 26, 2024

Roivant Sciences' CIO Mayukh Sukhatme sells $10.6m in shares By Investing.com - Investing.com South Africa

Dec 26, 2024
pulisher
Dec 26, 2024

Roivant sciences president Eric Venker sells $1.15 million in shares - Investing.com

Dec 26, 2024
pulisher
Dec 21, 2024

Barclays PLC Buys 75,609 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat

Dec 21, 2024
pulisher
Dec 20, 2024

Mayukh Sukhatme Sells 412,584 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock - MarketBeat

Dec 20, 2024
pulisher
Dec 20, 2024

Roivant sciences executive sells common shares worth $4.97 million - Investing.com India

Dec 20, 2024
pulisher
Dec 20, 2024

Geode Capital Management LLC Acquires 1,460,205 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat

Dec 20, 2024
pulisher
Dec 19, 2024

Retirement Systems of Alabama Buys 112,286 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat

Dec 19, 2024
pulisher
Dec 17, 2024

Ramaswamy Urges BuzzFeed to Cut Jobs, Air More Conservative Voices - MSN

Dec 17, 2024
pulisher
Dec 16, 2024

Trump administration will have financial ties to biotechs - BioCentury

Dec 16, 2024
pulisher
Dec 12, 2024

State Street Corp Buys 1,118,561 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat

Dec 12, 2024
pulisher
Dec 09, 2024

Roivant Sciences Ltd. (NASDAQ:ROIV) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Dec 09, 2024
pulisher
Dec 07, 2024

What is Leerink Partnrs' Estimate for ROIV Q3 Earnings? - MarketBeat

Dec 07, 2024
pulisher
Dec 06, 2024

Several Positive Developments Lifted Roivant (ROIV) in Q3 - Insider Monkey

Dec 06, 2024
pulisher
Dec 06, 2024

Edgestream Partners L.P. Buys Shares of 48,226 Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat

Dec 06, 2024

Roivant Sciences Ltd Stock (ROIV) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$21.80
price up icon 4.81%
$73.47
price up icon 2.14%
$22.10
price up icon 16.13%
$367.97
price up icon 2.52%
biotechnology ONC
$218.70
price up icon 4.10%
$117.25
price up icon 4.75%
Cap:     |  Volume (24h):